ASH 2024 | Outcomes of alloSCT in older patients aged over 70 years with myelofibrosis

So we retrospectively looked at the CIBMTR registry data set. Looking at myelofibrosis patients who have received an allogeneic hematopoietic stem cell transplant, we identified 872 patients. Out of these, 51 patients were over the age of 70 years. So this is an area of active debate. And the current guidelines suggest that patients who are over the age of 65 years should only get transplants if they are on a clinical study determining the efficacy. So it’s not considered the standard practice. So we wanted to look at those few patients who are elderly over the age of 70 and did receive an allogeneic stem cell transplant for intermediate to high-risk myelofibrosis. And we saw slightly poor outcomes compared to younger patients, but the two-year overall survival was 59%, and the two-year disease-free survival was 31%. So given that these patients have a survival in the order of months and often less than a year without transplant, over 50% of patients survived two years beyond transplantation. So allogeneic hematopoietic stem cell transplant should be considered in elderly fit myelofibrosis patients and we will build on this data set and we’ll publish findings in patients who are over the age of 65 years.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.